Galectin Therapeutics a buy on break above 200MA
Very bullish action in the stock which has been stalled by the 200MA acting as strong resistance.
A break above could see a nice bull run to FIB Resistance @ $5.
Indicator bullish.
Average analysts price target $11
Average analysts recommendation BUY
Short interest 8.47%
Company profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA
A break above could see a nice bull run to FIB Resistance @ $5.
Indicator bullish.
Average analysts price target $11
Average analysts recommendation BUY
Short interest 8.47%
Company profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA